CTOs on the Move

BioAmber

www.bio-amber.com

 
BioAmber is a renewable chemistry company. We use agricultural crops and transform them into green chemicals that directly substitute chemicals derived from oil. BioAmber combines industrial biotechnology and chemical catalysis into a process that offers a better carbon footprint than petrochemicals. In addition to moving away from petroleum, our process consumes CO2, directly reducing greenhouse gas emissions and aiding in the fight against global warming. Bioamber is today the only producer of bio-succinic acid, a chemical building block used in a number of applications, such as plastics, polyurethane, solvents, personal care, plasticisers, etc.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.bio-amber.com
  • 1250 Rene-Levesque Blvd. West Suite 4110
    Montreal, QC CAN H3B 4W8
  • Phone: 514.844.8000

Executives

Name Title Contact Details

Similar Companies

Labviva

Revolutionizing life sciences procurement. AI-powered digital marketplace for complete transparency into your supply chain Labviva integrates with your existing purchasing software to provide you with actionable insights to make better decisions. Keep your current suppliers, contract pricing, and your purchasing software and processes. Our digital marketplace offers unparalleled visibility into your procurement process, to empower informed decisions to drive science forward without interruptions to your research.

BioLink Life Sciences

BioLink Life Sciences is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

XenoPort

XenoPort, Inc. is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aytu BioScience

Aytu BioScience, Inc. is a specialty healthcare company focused on developing treatments for urological and related conditions. The Company is currently completing Phase 3 clinical development for its lead therapeutic candidate Zertane™, an orally disintegrating tablet (ODT) formulated specifically for the on-demand treatment of premature ejaculation (PE). The Company`s therapeutic pipeline is supported in part by its first-in-class RedoxSYS® System, which provides the only complete assessment of patients` redox status and enables identification of a broad variety of disorders where redox is implicated. Clinical studies are underway utilizing the RedoxSYS system in male fertility. The Company also recently acquired and is commercializing FDA-approved ProstaScint® (capromab pendetide), a radio-labeled monoclonal antibody, that targets Prostate Specific Membrane Antigen (PSMA), a protein uniquely expressed by prostate tissue. The Company`s strategy is to develop its core therapeutic and diagnostic assets while building an innovative pipeline of established marketed products and late-stage development assets.

Glycomine

There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA approved treatment. Glycomine develops therapeutics for diseases which have no treatment options.